Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Commercial Officer | May 02, 2024 | May 06, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 02, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,767 |
Ending reported balance
After 2024-05-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 71,767 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-05-02 · Sale · Disposed 5,000 · Balance 66,767 F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,277 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 4,277 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 7, 2017 23:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,749 | $93.95 | $164,318.55 |
DisclosureSEC source: 0001140361-17-010942 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,510 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,917 | $95.61 | $1,139,396.29 |
DisclosureSEC source: 0001140361-17-009672 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,259 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · price: Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan. F3 · price: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,467 | $95.61 | $1,765,648.34 |
DisclosureSEC source: 0001140361-16-081092 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,342 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $94.82 to $96.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.